Equities research analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Separately, Lake Street Capital cut their price objective on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, August 23rd.
Check Out Our Latest Stock Analysis on Evogene
Evogene Price Performance
Evogene (NASDAQ:EVGN – Get Free Report) last posted its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The firm had revenue of $0.91 million for the quarter.
Hedge Funds Weigh In On Evogene
An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets raised its position in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) by 30.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent SEC filing. 10.40% of the stock is owned by hedge funds and other institutional investors.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
See Also
- Five stocks we like better than Evogene
- 3 REITs to Buy and Hold for the Long Term
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- How to Calculate Return on Investment (ROI)
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.